Aldeyra Therapeutics, Inc. ALDX
1.21
(0.01)
(0.82%)
as of 25 Sep
- Market cap
- $73.6M
- P/E
- 0.0×
Follow ALDX
Insider Buys
alert about insiders buying in the last 12 month
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(64.31%) | (58.73%) | (51.76%) | (49.48%) | |
| (44.27%) | (38.32%) | (34.28%) | (34.80%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(88.19%) | (76.97%) | (65.25%) | (61.08%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(0.67) | (0.56) | (0.43) | (0.37) | |
Free Cash Flow |
(40.08) | (33.35) | (25.99) | (22.04) | |
Capital Expenditures |
— | — | — | (0.02) | |
| Other line items | |||||
Cash ROIC |
(28.68%) | (25.74%) | (21.22%) | (26.54%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.93 | 0.99 | 0.95 | 0.96 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | (2.18) | |
Capex/Depreciation |
0.00 | 0.00 | 0.00 | 0.52 | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.67) | (0.56) | (0.43) | (0.37) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
— | — | — | 0.00 | |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates